Dataset from A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Twelve Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis With or Without Psoriatic Arthritis Comorbidity
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00012344
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
创建时间：
2025-12-16
